LEGN - Legend Biotech Corp. Forward Price-to-Revenue Multiple

legendbiotech.com (LEGN) - corporate logo

Geographic reach across the US, Europe, and China creates a robust foundation for the expansion of Legend Biotech (LEGN). The forward P/S ratio confirms this trend, where 2.60 reflects the baseline level of the metric. Growth is supported by alliances with global pharma behemoths and the high cost of innovative treatments, which are consistently reimbursed by insurance companies.

legendbiotech.com - LEGN Projected Price to Revenue (period 07/04/2022 - 11/13/2026)

Legend Biotech Corp. - analytical breakdowns and key metrics (LEGN)

- market price and analyst price targets:
Price Chart Legend Biotech Corporation|LEGN - Price Target Chart
- market capitalization statistics:
Market Valuation Legend Biotech Corp.|LEGN - Value Adjusted for Debt and Cash
- business book valuation details:
Book Value per Share Legend Biotech|LEGN - Book Value of Business|Market Capitalization to Book Value Ratio legendbiotech.com|LEGN - Company Assets
- debt and solvency information:
Debt to Equity Legend Biotech|LEGN - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Legend Biotech|LEGN - Company Cumulative Debt|Debt to Book Value Legend Biotech Corp.|LEGN - Company Long-Term Loans and Borrowings|Company Current Liabilities Legend Biotech|Quick Ratio legendbiotech.com
- financial results and valuation multiples details:
LEGN - Final Profit|Projected Future Earnings Legend Biotech|LEGN - Market Cap to Earnings|Future Price to Earnings Legend Biotech Inc.|LEGN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Legend Biotech Corp.|LEGN - Operating profit EBITDA|Earnings per share for the last twelve months Legend Biotech|LEGN - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months legendbiotech.com|LEGN - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Legend Biotech
- revenue and sales proceeds data:
LEGN - Company Revenue|Projected Sales Volume Legend Biotech Corporation|LEGN - Price to Sales|Forward P/S Multiple Legend Biotech Corp.
Initial company analysis:Legend Biotech Corporation (LEGN)
Original product of Legend Biotech Corp.

The forward P/S reflects the ratio of current market value to expected revenue, allowing for an assessment of the investor's premium paid for potential revenue growth amid uncertainty. By analyzing the forward price-to-sales ratio, one can evaluate the capitalization stability of Legend Biotech (LEGN), based on the commercial success of Carvykti CAR-T therapy and the strategic alliance with J&J, which ensures the scaling of sales.

Key competitors

Price-to-Projected Revenue Ratio Sana Biotechnology, Inc. SANA|Autolus Therapeutics PLC - Price-to-Projected Revenue Ratio|ALLO: Forward Price-to-Revenue Multiple|Forward Price to Sales RNAC (Selecta Biosciences Inc.)|CLLS: Forward P/S Multiple|Projected Price to Revenue cariboubio.com CRBU|TIL (Instil Bio) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Genenta GNTA|Price-to-Projected Revenue Ratio Century Therapeutics (IPSC)|jaspertherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple SNTI (Senti Biosciences)|Adaptimmune Therapeutics plc (ADAP) - Market Cap to Future Revenue Ratio|CERO: Forward Price-to-Revenue Multiple|Forward Price to Sales TCRT (Alaunos Therapeutics)|ACHL (achillestx.com) - Forward Price-to-Revenue Multiple|CRGX: Price to Expected Revenue Ratio|PSTX (Poseida Therapeutics) - Forward P/S Multiple|TSVT: Forward Price to Sales|Forward P/S Multiple GRCL